Coronary disease & ACSResearch article
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease
- Narrative review
Authors' conclusion
Lipid lowering and inflammation inhibition are not in conflict but are synergistic.
Study context
- Population
- CAD patients on guideline-directed medical care, including statins
- Comparison
- Low-dose colchicine added to guideline-directed care incl. statins
Main finding
As reported in the abstract
MACE with low-dose colchicine (0.5 mg/d orally)
MACE reduction in stable atherosclerosis
31%
MACE reduction after recent MI
23%
Further findings
Inflammation (high-sensitivity C-reactive protein (hsCRP)) vs low-density-lipoprotein cholesterol (LDL-C) as determinant of CV death and all-cause mortality in statin-treated patients
- hsCRP is a more powerful determinant than LDL-C
Contraindications and interactions
- Contraindicated in significant renal or liver dysfunction; temporarily discontinue with clarithromycin, ketoconazole, cyclosporine
Original publication
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease. J Am Coll Cardiol. Published 15 August 2023. doi:10.1016/j.jacc.2023.05.055
Summarised from the published abstract; every number is checked against it